Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Q3 2021 Earnings Presentation
14 slides from Syndax Pharmaceuticals's earnings presentation, November 2021
Slide 1: 3Q21 Earnings Presentation
Determined to realize a future in which people with cancer live longer and better than ever before 3Q21 EARNINGS PRESENTATION
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Syndax pipeline targets indications with significant unmet need
Syndax pipeline targets indications with significant unmet need Global partnership signed with Incyte Menin Inhibitor Anti–CSF-1R Program Development Program (SNDX-5613) Opportunities (Axatilimab) • NPM1 and MLLr acute leukemias • Macrophage driven diseases • Focused on expanding clinical pipeline t
Slide 4: AUGMENT-101 registration trials underway in distinct patient populations
AUGMENT-101 registration trials underway in 3 distinct patient populations Independent, pivotal trials 64 adults AUGMENT-101 AUGMENT-101-2A: MLLr ALL + up to 10 peds R/R MLLr or 64 adults AUGMENT-101-2B: MLLr AML mNPM1 + up to 10 peds acute leukemia 64 adults AUGMENT-101-2C: NPM1 mut AML + up to 10
Slide 5: ASH abstract for AUGMENT-101 highlights robust clinical activity
ASH abstract for AUGMENT-101 highlights robust clinical activity Summary of ASH abstract (June 2021 data cut) Overall Selected baseline demographics (n = 54) Median age 49 years # Prior lines of therapy, Median (Range) 3 (1-12) # Patients with prior venetoclax 31 (57%) # Patients with prior transpla
Slide 6: Trials testing expanded opportunities for SNDX-5613 to initiate in 1H22
Trials testing expanded opportunities for SNDX-5613 to initiate in 1H22 BEAT-AML: AUGMENT-102: INTERCEPT: Frontline Ven/Aza combo R/R Chemo combo MRD-progression in AML Phase 1/3; Frontline Phase 1; Relapsed or refractory Phase 1; Relapsed or refractory mNPM1 or MLLr AML mNPM1 or MLLr AML/ALL mNPM1
Slide 7: SNDX-5613: moving into frontline meaningfully expands market potential
SNDX-5613: moving into frontline meaningfully expands market potential with additional patients and increasing duration of Tx Potential best/first-in-class agent • Clear efficacy in refractory, advanced NPM1 and MLLr acute leukemia • High percentage of MRD negative responses Profile supports use in
Slide 8: A broad, long-term, global collaboration between Syndax and Incyte
A broad, long-term, global collaboration between Syndax and Incyte to accelerate and maximize the development of axatilimab Global co-dev for all indications; SNDX funds 45% of global trials, INCY funds 100% of regional trials • $117M upfront 50:50 profit split; SNDX has option to • $35M equity @ pr
Slide 9: ASH abstract highlights axatilimab's broad efficacy and tolerability
ASH abstract highlights axatilimab’s broad efficacy and tolerability Summary of ASH abstract (June 2021 data cut) Selected baseline demographics Overall (n = 40) Median age (range) 59 years (16-73) # Prior lines of therapy, Median (Range) 4 (1-11) # Patients with prior ibrutinib 25 (63%) # Patients
Slide 10: Ongoing global pivotal trial for axatilimab in chronic GVHD
: ongoing global pivotal trial for axatilimab in chronic GVHD Inclusion criteria: 0.3 mg/kg Q2W 70 patients Randomization • 6 years and older R/R 1:1:1 1 mg/kg Q2W 70 patients cGVHD • Recurrent or refractory 3 mg/kg Q4W 70 patients active cGVHD after at least 2 lines of systemic FPFV in Topline ther
Slide 11: Axatilimab: moving up the treatment paradigm in cGVHD and into new indications
Axatilimab: moving up the treatment paradigm in cGVHD and into new indications meaningfully expands market potential Potential best/first-in-class agent • Clear efficacy in chronic Graft vs Host disease • Clinical evidence supporting reversal of fibrosis Profile supports expanded use within cGVHD an
Slide 12: Proven ability to build the pipeline
Proven ability to build the pipeline From UCB Business development continues to be a core strength of our business Axatilimab Clinical development leadership enables competitive advantage From Allergan/Vitae Established relationships enhance Menin-MLL identification and access to quality assets inhi
Slide 13: Financial highlights and FY 2021 financial guidance
Financial highlights and FY 2021 financial guidance Ticker SNDX (NASDAQ) Cash and short-term investments (as of September 30, 2021) $229.7 million Shares Outstanding* (as of September 30, 2021) 52.2 million 2021 Operating Expense Guidance FY 2021 Research and Development $90-100 million Total Operat
Slide 14: Thank you. Questions?
7 Thank you. Questi ons? ge
Syndax Pharmaceuticals — Q3 2021 Earnings Presentation on 6ix